Company intelligence / Profile preview

MedCu Technologies

Ownership: Private
Development stage: Other

Overview

MedCu’s copper-based wound dressings are FDA-cleared and CE-marked. They have demonstrated broad-spectrum antimicrobial efficacy—including against antibiotic-resistant bacteria—and are used globally for acute and chronic wounds. Over 35 peer-reviewed articles support their safety and effectiveness in clinical settings.

Therapeutic areas: DermatologyEndocrinologyInfectious DiseasesOther
Modalities: Device (wound dressing)Nanoparticle (copper oxide microparticles)
Industry: Consumable Medical Devices

Partnerships

Not explicitly listed; distributes globally with various partners/distributors.

Beyond the preview

Go deeper on MedCu Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MedCu Technologies.

Explore the full profile